Equities research analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce earnings of ($0.27) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.28). CymaBay Therapeutics reported earnings of ($0.29) per share during the same quarter last year, which suggests a positive year over year growth rate of 6.9%. The business is scheduled to announce its next quarterly earnings report on Wednesday, May 10th.
On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($0.86) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.59). For the next financial year, analysts anticipate that the firm will report earnings of ($0.98) per share, with EPS estimates ranging from ($1.31) to ($0.68). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.02.
A number of analysts recently commented on CBAY shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target (up from $6.00) on shares of CymaBay Therapeutics in a research report on Monday, March 27th. Zacks Investment Research downgraded CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. Finally, Piper Jaffray Companies increased their price target on CymaBay Therapeutics from $5.00 to $6.50 and gave the company an “overweight” rating in a research report on Friday, March 24th.
A hedge fund recently bought a new stake in CymaBay Therapeutics stock. J. Goldman & Co LP purchased a new position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 330,207 shares of the biopharmaceutical company’s stock, valued at approximately $571,000. J. Goldman & Co LP owned 1.41% of CymaBay Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 27.88% of the company’s stock.
Shares of CymaBay Therapeutics (NASDAQ:CBAY) traded down 0.47% during trading on Thursday, reaching $4.22. The company’s stock had a trading volume of 232,001 shares. The stock’s market cap is $121.33 million. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $4.44. The stock has a 50-day moving average of $3.88 and a 200-day moving average of $2.41.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/analysts-expect-cymabay-therapeutics-inc-cbay-will-announce-earnings-of-0-27-per-share/1739692.html
Receive News & Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.